<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1VUEPJ4Z_TESAAXKWJXBOGOGOTAABXD6 qc-＆fc = 20230708114047＆utm_source = chrome＆utm_medium = rss＆ff = 20250222071750＆utm_campaign = PubMed-2＆v = 2.18.0.post9 +E462414<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250222071750&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期六，2025年2月22日12:17:52 +0000</lastbuilddate><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>血压的盐敏感性：机制和性别特异性差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/39984695/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>血压的盐敏感性（SSBP）是患有或没有高血压的个体的心血管疾病的独立危险因素，但是，SSBP的机制和管理仍然不清楚，主要是因为这种疾病的诊断依赖在诊所中不可行SSBP过多... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">血压的盐敏感性（SSBP）是患有或没有高血压的个体的心血管疾病的独立危险因素，但是，SSBP的机制和管理仍然不清楚，主要是因为这种疾病的诊断依赖在诊所中不可行在任何年龄段的女性中，SSBP过度有助于这种逆转，但是许多使用盐负荷止损方案对SSBP进行了严格评估的临床研究证实，SSBP在女性中比男性更普遍，包括在此期间评论，我们讨论了SSBP的性别特定机制。自身免疫性疾病和有丝分裂原激活的蛋白激酶信号传导途径，并突出了从DAHL盐敏感大鼠模型中学到的局限性和经验教训。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39984695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39984695</a> <a href=https://doi.org/10.1038/s41569-025-01135-0>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39984695</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Sepiso K Masenga</dc:creator><dc:creator>纳尔逊·旺迪拉（Nelson Wandira）</dc:creator><dc:creator> Giuliana Cattivelli-Murdoch</dc:creator><dc:creator>穆罕默德·萨利姆（Mohammad Saleem）</dc:creator><dc:creator>希瑟·比斯利（Heather Beasley）</dc:creator><dc:creator>宁托欣顿</dc:creator><dc:creator>lale a ertuglu</dc:creator><dc:creator> Naome Mwesigwa</dc:creator><dc:creator>托马斯·克利曼（Thomas R Kleyman）</dc:creator><dc:creator>安妮·基拉博（Annet Kirabo）</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>自然评论</dc:source><dc:title>血压的盐敏感性：机制和性别特异性差异</dc:title><dc:identifier>PMID：39984695</dc:identifier><dc:identifier> doi：10.1038/s41569-025-01135-0</dc:identifier></item><item><title>核小体开关素肝炎病毒感染</title><link/>https://pubmed.ncbi.nlm.nih.gov/39983728/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>慢性肝炎病毒（HBV）感染是一种导致肝病和肝细胞癌的导致病原体，HBV建立了一个独立的微型鲜膜体，由病毒式封闭的闭合圆形DNA（CCDNA）基因组和宿主组织组成X基因必须在感染后立即表达，以诱导宿主沉默因子的降解，但是，SMC5/6复合物。 CCCDNA染色化和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">慢性肝炎病毒（HBV）感染是一种导致肝病和肝细胞癌的导致病原体，HBV建立了一个独立的微型鲜膜体，由病毒式封闭的闭合圆形DNA（CCDNA）基因组和宿主组织组成X基因必须在感染后立即表达，以诱导宿主沉默因子的降解，但是，SMC5/6复合物。 CCCDNA染色体和X基因转录通过建立一个重构的病毒式微型体平台来理解，我们发现CCCDNA中的核占用率调节了X转录。原发性肝细胞中的转录和HBV感染。并代表了治疗慢性HBV感染的潜在治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39983728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39983728</a> <a href=https://doi.org/10.1016/j.cell.2025.01.033>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39983728</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>尼古拉斯·普雷斯科特（Nicholas A Prescott）</dc:creator><dc:creator>特雷西·比亚科（Tracy Biaco）</dc:creator><dc:creator>安德烈斯·曼西多（AndrésMansisidor）</dc:creator><dc:creator> Yaron Bram</dc:creator><dc:creator>贾斯汀·伦德曼（Justin Rendleman）</dc:creator><dc:creator> Sarah C Faulkner</dc:creator><dc:creator>阿比盖尔柠檬</dc:creator><dc:creator>克里斯汀·林</dc:creator><dc:creator>雷切尔·蒂尔斯基（Rachel Tiersky）</dc:creator><dc:creator> Eralda Salataj</dc:creator><dc:creator> Liliana Garcia-Martinez</dc:creator><dc:creator> Rodrigo L Borges</dc:creator><dc:creator> Lluis Morey</dc:creator><dc:creator>皮埃尔·雅克·哈马德（Pierre-Jacques Hamard）</dc:creator><dc:creator>理查德·P·科切（Richard P Koche）</dc:creator><dc:creator> Viviana I Risca</dc:creator><dc:creator>罗伯特·施瓦茨（Robert E Schwartz）</dc:creator><dc:creator> Yael David</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>细胞</dc:source><dc:title>核小体开关素肝炎病毒感染</dc:title><dc:identifier>PMID：39983728</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.033</dc:identifier></item><item><title>遗传性心肌病的研究和治疗的进步</title><link/>https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description>心肌是心肌的主要疾病。和心律不齐的心肌病（ACM），右，左或双室受累和心律不齐与不成比例收缩功能障碍。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>牢房</b>2025年2月20日; 188（4）：901-918</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心肌是心肌的主要疾病。和心律不齐的心肌病（ACM），右，左或双室受累和心律不齐与不成比例疾病分子基础的收缩功能障碍正在为诊断和管理方面的精确度延伸，并揭示了区分临床特征的机制。基于抵消病理生理学的药物以及旨在拦截疾病进展并恢复心脏生理学的新兴基因疗法。这些发现共同对心脏生物学有了基本的见解，并为心肌病患者带来了新时代。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39983674</a> <a href=https://doi.org/10.1016/j.cell.2025.01.011>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39983674</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>维多利亚n帕克</dc:creator><dc:creator>Sharlene M Day</dc:creator><dc:creator> Neal K Lakdawala</dc:creator><dc:creator>埃里克·阿德勒（Eric D Adler）</dc:creator><dc:creator> Iacopo Olivotto</dc:creator><dc:creator>克里斯汀·塞德曼（Christine E Seidman）</dc:creator><dc:creator>卡罗琳·霍</dc:creator><dc:date>2025-02-21</dc:date><dc:source>细胞</dc:source><dc:title>遗传性心肌病的研究和治疗的进步</dc:title><dc:identifier>PMID：39983674</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.011</dc:identifier></item><item><title> Plasmodesmata充当非常规的膜接触位点，以恢复植物中细胞间分子交换</title><link/>https://pubmed.ncbi.nlm.nih.gov/39983675/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>膜接触位点（MCS）是细胞内通信的基础，但是它们在细胞间通信中的作用仍然出乎意料。 - 类似于其他MCS的细胞界面，ER-PM应用由蛋白质 - 脂质的绑扎复合物控制，但独特的是，这具有细胞间通信。结合高分辨率... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>牢房</b>2025年2月20日； 188（4）：958-977.e23。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">膜接触位点（MCS）是细胞内通信的基础，但是它们在细胞间通信中的作用仍然出乎意料。 - 类似于其他MCS的细胞界面，ER-PM应用由蛋白质 - 脂质的绑扎复合物控制，但独特的是，这具有细胞间通信。结合高分辨率显微镜，分子动力学以及药物和遗传方法，我们表明细胞传输是通过多个C2结构域的跨膜结构蛋白（MCTPS）3、4和6 ER-PM TETHERS和6 ER-PM TETHERS和磷脂酰素蛋白质醇的蛋白质（MCTPS）蛋白质（MCTPS）蛋白质（MCTPS）组合调节-4-磷酸盐（PI4P）脂质。 SAC7是一种ER定位的PI4P磷酸酶，调节MCTP4在平原上的积累，并以细胞类型的特异性方式调节细胞 - 细胞运输能力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39983675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39983675</a> <a href=https://doi.org/10.1016/j.cell.2024.11.034>​​|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39983675</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>杰西卡·佩雷斯·桑乔（JessicaPérez-Sancho）</dc:creator><dc:creator>大麻烟熏瓦斯卡</dc:creator><dc:creator>Gwennogan Dubois</dc:creator><dc:creator>玛丽·格拉维尔（Marie Glavier）</dc:creator><dc:creator> Sujith Sritharan</dc:creator><dc:creator>塔蒂亚娜（Tatiana）的莫拉斯（Moraes）</dc:creator><dc:creator>霍顿·莫罗（Hortense Moreau）</dc:creator><dc:creator>维克多·迪特里奇（Victor Dietrich）</dc:creator><dc:creator> Matthieu P Platre</dc:creator><dc:creator> Andrea Paterlini</dc:creator><dc:creator> Ziqiang P Li</dc:creator><dc:creator> Laetitia Fouillen</dc:creator><dc:creator>玛格丽·格里森（Magali S Grison）</dc:creator><dc:creator> Pepe Cana-Quijada</dc:creator><dc:creator> FrançoiseImmel</dc:creator><dc:creator> Valerie Wattelet</dc:creator><dc:creator> Mathieu Ducros</dc:creator><dc:creator> Lysiane Brocard</dc:creator><dc:creator> ClémentChambaud</dc:creator><dc:creator> Yonging Luo</dc:creator><dc:creator> Priya Ramakrishna</dc:creator><dc:creator>文森特·贝尔（Vincent Bayle）</dc:creator><dc:creator> Linnka Lefebvre-Legendre</dc:creator><dc:creator> Stéphaneclaverol</dc:creator><dc:creator> Matej Zabrady</dc:creator><dc:creator> Pascal GP Martin</dc:creator><dc:creator>沃尔夫冈·布希（Wolfgang Busch）</dc:creator><dc:creator>玛丽·巴贝隆</dc:creator><dc:creator>Jens Tilsner</dc:creator><dc:creator> YrjöHelariutta</dc:creator><dc:creator> Eugenia Russinova</dc:creator><dc:creator>安托万·塔利（Antoine Taly）</dc:creator><dc:creator>伊冯·耶拉伊斯</dc:creator><dc:creator>Emmanuelle M Bayer</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>细胞</dc:source><dc:title>Plasmodesmata充当非常规的膜接触位点，以恢复植物中细胞间分子交换</dc:title><dc:identifier>PMID：39983675</dc:identifier><dc:identifier> doi：10.1016/j.cell.2024.11.034</dc:identifier></item><item><title>细胞对RNA损伤的反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/39983673/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description> RNA在蛋白质生物合成中起着核心作用，并进行不同的调节和催化功能，使其对DNA的所有过程必不可少。长期以来，由于大多数RNA分子的短暂性，我们回顾了最新的研究，因此长期以来RNA故事相对无关紧要。通过揭示... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>牢房</b>2025年2月20日; 188（4）：885-900。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RNA在蛋白质生物合成中起着核心作用，并进行不同的调节和催化功能，使其对DNA的所有过程必不可少。长期以来，由于大多数RNA分子的短暂性，我们回顾了最新的研究，因此长期以来RNA故事相对无关紧要。通过揭示复杂的RNA损伤反应来挑战这种观点，这些反应确定细胞暴露于核酸损伤剂并促进RNA病变的分辨率。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39983673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39983673</a> <a href=https://doi.org/10.1016/j.cell.2025.01.005>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39983673</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>杰奎琳·绳索</dc:creator><dc:creator>Shubo Zhao</dc:creator><dc:creator>卡拉·恩·恩格尔（Carla M Engel）</dc:creator><dc:creator>朱利安·斯廷格尔（Julian Stingele）</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>细胞</dc:source><dc:title>细胞对RNA损伤的反应</dc:title><dc:identifier>PMID：39983673</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.005</dc:identifier></item><item><title>溶质载体：新陈代谢的看门人</title><link/>https://pubmed.ncbi.nlm.nih.gov/39983672/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>溶质载体（SLC）蛋白在过去十年中进行的研究越来越多，在越来越多的研究中，许多SLC的物理基板和功能仍在研究这一观点，但在研究中越来越多地研究了这一观点，但在维持细胞和有机稳态方面起着关键作用。 SLC生物学和提议定义SLC底物的基于证据的框架。技术，包括人... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>牢房</b>2025年2月20日； 188（4）：869-884。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">溶质载体（SLC）蛋白在过去十年中进行的研究越来越多，在越来越多的研究中，许多SLC的物理基板和功能仍在研究这一观点，但在研究中越来越多地研究了这一观点，但在维持细胞和有机稳态方面起着关键作用。 SLC生物学和提议定义SLC底物的基于证据的框架。技术，包括人类遗传学，生物化学以及计算和结构方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39983672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39983672</a> <a href=https://doi.org/10.1016/j.cell.2025.01.015>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39983672</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Artem Khan</dc:creator><dc:creator> Yuyang Liu</dc:creator><dc:creator>马克·加德</dc:creator><dc:creator>蒂莫西·C肯尼</dc:creator><dc:creator>KıvançBirsoy</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>细胞</dc:source><dc:title>溶质载体：新陈代谢的看门人</dc:title><dc:identifier>PMID：39983672</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.015</dc:identifier></item><item><title>纠正至：2024 ESC管理慢性冠状动脉综合征指南：由欧洲心脏神衷力协会（ESC）认可的欧洲心脏病学会慢性冠状动脉综合征管理工作组开发</title><link/>https://pubmed.ncbi.nlm.nih.gov/39982387/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月21日：EHAF079。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39982387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39982387</a> <a href=https://doi.org/10.1093/eurheartj/ehaf079>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39982387</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>纠正至：2024 ESC管理慢性冠状动脉综合征指南：由欧洲心脏神衷力协会（ESC）认可的欧洲心脏病学会慢性冠状动脉综合征管理工作组开发</dc:title><dc:identifier>PMID：39982387</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf079</dc:identifier></item><item><title>急性冠状动脉综合征中的二硝酸钛 - 氧化物涂层与洗脱支架：单个患者数据荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description>结论：在ACS患者中，TINOS与DES相比与CD，MI和支架血栓形成率明显较低，与MACE和TLR相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月21日：EHAF098。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在急性冠状动脉综合征（AC）中，可以延迟植入药物的植入部位的血管愈合（DES）比较了裸金属支架的增生。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：进行了系统的审查和个人参与者的数据荟萃分析，对TINOS与DES进行AC的治疗进行了比较（Prospero：CRD42024514342）。死亡（CD），心肌梗塞（MI）和缺血驱动的靶病变血运重建（TLR）。使用带有随机斜率和分层基线危害的混合效应的COX回归模型来合并TLR和支架血栓形成。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者级数据（n = 2743）是从三个随机对照试验中获得的（tinos：n = 1620 vs. des：n = 1123）。 TINOS和DES之间的主要终点（12.6％vs. 16.2％；危险比[HR] .82，95％置信区间[CI] .67-1.00，P = .051），主要是由于相似的速率TLR（8.0％比8.1％； HR 1.05，95％CI .80-1.38，p = .733）。 ％CI .26-.81，p = .007），MI（5.2％vs. 9.6％； HR .56，95％CI .42-.75，P &lt;.001）和支架血栓形成（1.1％VS。 3.8％; HR .30，95％CI .17-.53 p &lt;.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在ACS患者中，TINOS与DES相比与CD，MI和支架血栓形成率明显较低，与MACE和TLR相似。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39981941</a> <a href=https://doi.org/10.1093/eurheartj/ehaf098>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39981941</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Thabo Mahendiran</dc:creator><dc:creator>弗雷德里克·布塞特（Frederic Bouisset）</dc:creator><dc:creator> PIM TONINO</dc:creator><dc:creator> Nico HJ Pijls</dc:creator><dc:creator> Jussi Sia</dc:creator><dc:creator> Kari Kervinen</dc:creator><dc:creator>费尔南多·里弗罗·克雷斯波（Fernando Rivero-Crespo）</dc:creator><dc:creator>彼得·尤尼</dc:creator><dc:creator>Bruno Roza da Costa</dc:creator><dc:creator> Carlos Collet</dc:creator><dc:creator> Takuy​​a Mizukami</dc:creator><dc:creator> Pasi Karjalainen</dc:creator><dc:creator>伯纳德·德·布鲁恩（Bernard de Bruyne）</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>急性冠状动脉综合征中的二硝酸钛 - 氧化物涂层与洗脱支架：单个患者数据荟萃分析</dc:title><dc:identifier>PMID：39981941</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf098</dc:identifier></item><item><title>心房颤动导管消融，脑糖性功能和认知性能</title><link/>https://pubmed.ncbi.nlm.nih.gov/39981927/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>结论：AF患者通过DTI-ALP指数测量的脑糖性功能受损，介导AF和认知能力下降之间的关联，并在消融治疗后得到改善。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025年2月21日：EHAF036。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：尚不清楚大脑胶囊系统是否是由心跳驱动的动脉脉动驱动的，并且负责大脑废物清除率，在心房颤动（AF）中受损并介导与AF相关的认知功能障碍这项研究是评估AF的大脑糖性变化，其在认知功能中的作用以及导管消融是否可以改善糖化活性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这种情况下，预期的研究和健康对照的患者（HC）参加了脑磁共振成像和全面的神经心理电池。进行消融的患者手术后，重复了血管周空间（DTI-ALP）指数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总体而言，与HC相比，有87例AF和44例HC患者的ALPS指数较低（P = .016）阵发性AF患者（p = .044）。测试和stroop颜色和单词测试（所有p &lt;.05）表明，在接受消融疗法的50例患者中，糖性活性是AF和认知下降之间的中介（P） = .015）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：AF患者通过DTI-ALP指数测量的脑糖性功能受损，介导AF和认知能力下降之间的关联，并在消融治疗后得到改善。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39981927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39981927</a> <a href=https://doi.org/10.1093/eurheartj/ehaf036>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39981927</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>斋河郭</dc:creator><dc:creator>张张</dc:creator><dc:creator>XU Meng</dc:creator><dc:creator> Jing Jing</dc:creator><dc:creator> Yiran Hu</dc:creator><dc:creator> Yan Yao</dc:creator><dc:creator> ligang ding</dc:creator><dc:creator> Lihui Zheng</dc:creator><dc:creator> Xingquan Zhao</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>心房颤动导管消融，脑糖性功能和认知性能</dc:title><dc:identifier>PMID：39981927</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf036</dc:identifier></item><item><title>对紫杉醇涂层气球的单个患者数据荟萃分析与小血管冠状动脉疾病的药物洗脱支架：仙女座研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description>结论：在接受新的SV-CAD的PCI患者中，PCB血管成形术与MACE的降低和与DES植入的限制相比，TLF的降低和TLF的差异不大。 DES不会改变比较更长的随访时比较当代设备的大型结论，以确认这些发现。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月21日：EHAF002：10.1093/Eurheartj/ehaf002。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在接受经皮冠状动脉干预（PCI）的随机临床试验中对于药物洗脱支架（DES）的植入，这些试验具有样本量的限制，第一年的相对安全性和效率仍然不确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：仙女座研究是一项合作，研究者发射的，单个患者数据荟萃分析，比较了PCB血管成形术和DES植入之间的3年临床结果，用于治疗NOVO SV-CAD（PubMed，Scopus，Sciencecendirect，Scienceirect，Scienceirect，Scienceirect，Scienceirect，Scienceirect，从2010年5月到2024年6月，搜索了符合条件的所有资格标准，并进行了搜索。需要：（i）（ii）SV-CAD的患者（III）治疗；分别是主要的不良心脏事件（MACE）和目标病变衰竭（TLF）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：三个随机试验的个人数据，包括总共1154例患者和1360个病变，在3年中，PCB与DES [危险比（HR）0.67 pusitive hr相比，PCB较低。间隔（CI）0.47-0.96]，由于较低的心肌梗死和目标血管重建的风险较低。 0.75，95％CI 0.58-0.96），但在两阶段分析中没有达到统计学意义（HR 0.67，95％CI 0.43-1.04）。在3年中，PCB和DES组之间的TLF没有显着差异。病变），在TLF方面显示出一致的结果（HR 0.87，95％CI 0.63-1.20）。 ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在接受新的SV-CAD的PCI患者中，PCB血管成形术与MACE的降低和与DES植入的限制相比，TLF的降低和TLF的差异不大。 DES不会改变比较更长的随访时比较当代设备的大型结论，以确认这些发现。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39981922</a> <a href=https://doi.org/10.1093/eurheartj/ehaf002>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39981922</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>西蒙妮·费兹（Simone Fezzi）</dc:creator><dc:creator> Daniele Giacoppo</dc:creator><dc:creator>格雷戈尔·法赫尼（Gregor Fahrni）</dc:creator><dc:creator> Azeem Latib</dc:creator><dc:creator>费尔南多·阿方索</dc:creator><dc:creator>安东尼奥·科伦坡</dc:creator><dc:creator>Felix Mahfoud</dc:creator><dc:creator>布鲁诺·谢勒（Bruno Scheller）</dc:creator><dc:creator> Raban Jeger</dc:creator><dc:creator> Bernardo Cortese</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>对紫杉醇涂层气球的单个患者数据荟萃分析与小血管冠状动脉疾病的药物洗脱支架：仙女座研究</dc:title><dc:identifier>PMID：39981922</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf002</dc:identifier></item><item><title>靶向INA的基因疗法以治疗威胁生命的心律失常：超出概念验证？</title><link/> https://pubmed.ncbi.nlm.nih.gov/39981909/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月21日：ehae930。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39981909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39981909</a> <a href=https://doi.org/10.1093/eurheartj/ehae930>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39981909</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator>帕特里克·卢根比尔（Patrick Lugenbiel）</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>靶向INA的基因疗法以治疗威胁生命的心律失常：超出概念验证？</dc:title><dc:identifier> PMID：39981909</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehae930</dc:identifier></item><item><title>取出垃圾：糖函数在心房颤动患者认知功能中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39981908/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 2月21日：EHAF040。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39981908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39981908</a> <a href=https://doi.org/10.1093/eurheartj/ehaf040>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39981908</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator> T Jared Bunch</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>取出垃圾：糖函数在心房颤动患者认知功能中的作用</dc:title><dc:identifier>PMID：39981908</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf040</dc:identifier></item><item><title>性别特异性风险因素的相关性日益增长</title><link/>https://pubmed.ncbi.nlm.nih.gov/39980454/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> EUR HEART J. 2025 2月21日； 46（8）：673-676：10.1093/eurheartj/ehaf021。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39980454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39980454</a> <a href=https://doi.org/10.1093/eurheartj/ehaf021>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39980454</guid><pubDate> Fri, 21 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Filippo Crea</dc:creator><dc:date> 2025-02-21</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>性别特异性风险因素的相关性日益增长</dc:title><dc:identifier>PMID：39980454</dc:identifier><dc:identifier> doi：10.1093/eurheartj/ehaf021</dc:identifier></item><item><title>膜蛋白插入期间的Secy Clanlocon伴侣蛋白折叠</title><link/>https://pubmed.ncbi.nlm.nih.gov/39978345/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description> SEC易位对于将膜蛋白插入脂质双层至关重要。在原核生物中。揭示了... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SEC易位对于将膜蛋白插入脂质双层至关重要。在原核生物中。揭示通道的细胞质和细胞外腔分别促进跨膜片段（TMS）的展开和折叠，分别释放出来的底物TMS凹槽在膜蛋白质组的折叠中引起全局缺陷。蛋白质导向通道，Secy易位可积极用作伴侣，采用多种机制来促进膜蛋白插入和折叠。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39978345/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39978345</a> <a href=https://doi.org/10.1016/j.cell.2025.01.037>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39978345</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator>小米OU</dc:creator><dc:creator> MA CHENGYING</dc:creator><dc:creator> Dongjie Sun</dc:creator><dc:creator> Jinkun Xu</dc:creator><dc:creator>杨王</dc:creator><dc:creator>小武</dc:creator><dc:creator>达利·王（Dali Wang）</dc:creator><dc:creator>歌阳</dc:creator><dc:creator>宁高</dc:creator><dc:creator>陈歌</dc:creator><dc:creator>长李</dc:creator><dc:date>2025-02-20</dc:date><dc:source>细胞</dc:source><dc:title>膜蛋白插入期间的Secy Clanlocon伴侣蛋白折叠</dc:title><dc:identifier>PMID：39978345</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.037</dc:identifier></item><item><title>视觉皮层中的电机和前庭信号允许自我与外部产生的视觉运动的分离</title><link/>https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description>知道我们是在移动还是在我们周围移动的东西是我们需要执行的最关键的感官歧视。我们发现，根据头部是静止还是经验，鼠标主视觉皮层（VISP）使用电动机，前庭和视觉运动信号来表示相同的视觉流信息。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">知道我们是在移动还是在我们周围移动的东西是我们需要执行的最关键的感官歧视。我们发现，鼠标主视觉皮层（VISP）使用电动机，前庭和视觉运动信号，以不同的视觉流信息表示相同的视觉流信息。与活动的活动相对于活动，我们发现运行抑制运行 - 式翻译输入，而翻译速度在运行和转换速度时会占主导地位。该运行和翻译信号提供了一个脑部的以自我为中心的参考框架，用于计算移动时内部生成的自我速度和实际速度通过并感知外部世界。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39978344</a> <a href=https://doi.org/10.1016/j.cell.2025.01.032>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39978344</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> MateoVélez-Fort</dc:creator><dc:creator>李·科塞尔</dc:creator><dc:creator>劳拉·波塔（Laura Porta）</dc:creator><dc:creator>克劳迪娅·克洛波斯（Claudia Clopath）</dc:creator><dc:creator>特洛伊·W·玛格丽（Troy W Margrie）</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>细胞</dc:source><dc:title>视觉皮层中的电机和前庭信号允许自我与外部产生的视觉运动的分离</dc:title><dc:identifier>PMID：39978344</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.01.032</dc:identifier></item><item><title>通过竞争蛋白质二聚化网络计算上下文计算</title><link/>https://pubmed.ncbi.nlm.nih.gov/39978343/？ 708114047＆ff = 20250222071750＆v = 2.18.0.post9+e462414<description> Many biological signaling pathways employ proteins that competitively dimerize in diverse combinations. These dimerization networks can perform biochemical computations in which the concentrations of monomer inputs determine the concentrations of dimer outputs. Despite their prevalence, little is known about the range of input-output computations that dimerization networks can perform and how it depends on network size and connectivity. Using a systematic computational approach, we demonstrate... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2025 Feb 11:S0092-8674(25)00105-9. doi: 10.1016/j.cell.2025.01.036. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Many biological signaling pathways employ proteins that competitively dimerize in diverse combinations. These dimerization networks can perform biochemical computations in which the concentrations of monomer inputs determine the concentrations of dimer outputs. Despite their prevalence, little is known about the range of input-output computations that dimerization networks can perform and how it depends on network size and connectivity. Using a systematic computational approach, we demonstrate that even small dimerization networks of 3-6 monomers are expressive, performing diverse multi-input computations. Further, dimerization networks are versatile, performing different computations when their protein components are expressed at different levels, such as in different cell types. Remarkably, individual networks with random interaction affinities, when large enough, can perform nearly all potential one-input network computations merely by tuning their monomer expression levels. Thus, even the simple process of competitive dimerization provides a powerful architecture for multi-input, cell-type-specific signal processing.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39978343/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39978343</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2025.01.036>10.1016/j.cell.2025.01.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39978343</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jacob Parres-Gold</dc:creator><dc:creator> Matthew Levine</dc:creator><dc:creator> Benjamin Emert</dc:creator><dc:creator> Andrew Stuart</dc:creator><dc:creator> Michael B Elowitz</dc:creator><dc:date> 2025-02-20</dc:date><dc:source>细胞</dc:source><dc:title>Contextual computation by competitive protein dimerization networks</dc:title><dc:identifier> pmid:39978343</dc:identifier><dc:identifier> doi:10.1016/j.cell.2025.01.036</dc:identifier></item><item><title> Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table</title><link/> https://pubmed.ncbi.nlm.nih.gov/39977258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description> The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Feb 20:ehaf069. doi: 10.1093/eurheartj/ehaf069. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although device approval is currently executed by Notified Bodies in the EU, it will be advantageous in the mid-term to consider a single EU regulatory agency for devices. In the short term, steps can be taken to transform the current system into a more efficient, predictable, cost-effective, and user-friendly service. Key strategies include the following: enhancing predictability of the approval process through use of early scientific advice from regulators; establishing unique regulatory pathways for CV orphan, paediatric, and innovative devices; promoting more efficient (re)certification of essential legacy CV devices; improving transparency of sponsor interactions with Notified Bodies; expanding the roles of the Expert Panels to assist in the approval of CV devices; promoting global regulatory harmonization, considering streamlined authorization of CV medical technologies across selected jurisdictions; developing an efficient system to monitor device safety; and ensuring funding for data collection platforms. Some strategies that could help include considering a pilot programme for joint approval processes of selected devices in partnership with other regions (ie US Food and Drug Administration); developing priority pathways for accelerated access to innovative or orphan devices; and increasing recognition of the importance of early feasibility studies in the EU.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39977258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39977258</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf069>10.1093/eurheartj/ehaf069</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39977258</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Stephan Windecker</dc:creator><dc:creator> Alan G Fraser</dc:creator><dc:creator> Piotr Szymanski</dc:creator><dc:creator> Martine Gilard</dc:creator><dc:creator> Thomas F Lüscher</dc:creator><dc:creator> Leila Abid</dc:creator><dc:creator> John Brennan</dc:creator><dc:creator> Robert Byrne</dc:creator><dc:creator> Lia Crotti</dc:creator><dc:creator> Inga Drossart</dc:creator><dc:creator> Jennifer Franke</dc:creator><dc:creator> Mario Gabrielli Cossellu</dc:creator><dc:creator> Ajay J Kirtane</dc:creator><dc:creator> Jana Kurucova</dc:creator><dc:creator> Mitchell Krucoff</dc:creator><dc:creator> Gearóid McGauran</dc:creator><dc:creator> Patrick O Myers</dc:creator><dc:creator> Donal B O&#39;Connor</dc:creator><dc:creator> Radosław Parma</dc:creator><dc:creator> Paul Piscoi</dc:creator><dc:creator> Archana Rao</dc:creator><dc:creator> Andrea Rappagliosi</dc:creator><dc:creator> Giulio Stefanini</dc:creator><dc:creator> Eigil Samset</dc:creator><dc:creator> Alphons Vincent</dc:creator><dc:creator> Ralph Stephan von Bardeleben</dc:creator><dc:creator> Franz Weidinger</dc:creator><dc:date> 2025-02-20</dc:date><dc:source> European heart journal</dc:source><dc:title> Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table</dc:title><dc:identifier> pmid:39977258</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf069</dc:identifier></item><item><title> Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title><link/> https://pubmed.ncbi.nlm.nih.gov/39976316/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description> This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2025 Feb 20:S0735-1097(24)10722-X. doi: 10.1016/j.jacc.2024.12.025. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39976316/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39976316</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2024.12.025>10.1016/j.jacc.2024.12.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39976316</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jonathan H Kim</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:creator> Benjamin D Levine</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Sharlene M Day</dc:creator><dc:creator> Elizabeth H Dineen</dc:creator><dc:creator> J Sawalla Guseh Ii</dc:creator><dc:creator> Andre La Gerche</dc:creator><dc:creator> Rachel Lampert</dc:creator><dc:creator> Matthew W Martinez</dc:creator><dc:creator> Michael Papadakis</dc:creator><dc:creator> Dermot M Phelan</dc:creator><dc:creator> Keri M Shafer</dc:creator><dc:creator> American Heart Association Leadership Committee of the Council on Clinical Cardiology</dc:creator><dc:creator> Council on Basic Cardiovascular Sciences</dc:creator><dc:creator> Council on Cardiovascular and Stroke Nursing</dc:creator><dc:creator> Council on Cardiovascular Surgery and Anesthesia</dc:creator><dc:creator> Council on Peripheral Vascular Disease</dc:creator><dc:creator> American College of Cardiology</dc:creator><dc:creator> Larry A Allen</dc:creator><dc:creator> Mats Börjesson</dc:creator><dc:creator> Alan C Braverman</dc:creator><dc:creator> Julie A Brothers</dc:creator><dc:creator> Silvia Castelletti</dc:creator><dc:creator> Eugene H Chung</dc:creator><dc:creator> Timothy W Churchill</dc:creator><dc:creator> Guido Claessen</dc:creator><dc:creator> Flavio D&#39;Ascenzi</dc:creator><dc:creator> Douglas Darden</dc:creator><dc:creator> Peter N Dean</dc:creator><dc:creator> Neal W Dickert</dc:creator><dc:creator> Jonathan A Drezner</dc:creator><dc:creator> Katherine E Economy</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:creator> Michael S Emery</dc:creator><dc:creator> Susan P Etheridge</dc:creator><dc:creator> Sabiha Gati</dc:creator><dc:creator> Belinda Gray</dc:creator><dc:creator> Martin Halle</dc:creator><dc:creator> Kimberly G Harmon</dc:creator><dc:creator> Jeffrey J Hsu</dc:creator><dc:creator> Richard J Kovacs</dc:creator><dc:creator> Sheela Krishnan</dc:creator><dc:creator> Mark S Link</dc:creator><dc:creator> Martin Maron</dc:creator><dc:creator> Silvana Molossi</dc:creator><dc:creator> Antonio Pelliccia</dc:creator><dc:creator> Jack C Salerno</dc:creator><dc:creator> Ankit B Shah</dc:creator><dc:creator> Sanjay Sharma</dc:creator><dc:creator> Tamanna K Singh</dc:creator><dc:creator> Katie M Stewart</dc:creator><dc:creator> Paul D Thompson</dc:creator><dc:creator> Meagan M Wasfy</dc:creator><dc:creator> Matthias Wilhelm</dc:creator><dc:date> 2025-02-20</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title><dc:identifier> pmid:39976316</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2024.12.025</dc:identifier></item><item><title> Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA</title><link/> https://pubmed.ncbi.nlm.nih.gov/39973625/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description>结论：这项研究表明，MeccirNA的快速降解以及线粒体活性氧的相关调节释放线粒体通透性过渡孔通过Meccirnas导致Meccirna Decradation Decradation Decradation degradation和Exenos Megenos Megenos Megenos Megenos Myternos cashement Mevers topernos Meption hf tose Myse hf hf。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070840. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells. Mitochondria-encoded circular RNAs (mecciRNAs) are attracting more attention, and several members of mecciRNAs have already been recognized in regulating mitochondrial functions. Mitochondria dysfunctions are well-known to participate in heart failure (HF). This study was designed to investigate the RNA metabolism of mecciRNAs and the relevant roles and potential application of mecciRNAs in HF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Compared with highly stable nuclear genome-encoded circular RNAs, the fast degradation feature of mecciRNAs is identified by RNA sequencing and a series of molecular, biochemical, and cellular experiments. The substantial protective effects of in vitro synthesized mecciRNAs were tested in both doxorubicin- and pressure overload-induced mouse models of HF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We discover that mecciRNAs are promptly degraded by an animal-conserved complex of helicase SUPV3L1 (suppressor of var1, 3-like protein 1) and endoribonuclease ELAC2 (elaC ribonuclease Z 2). MecciRNA degradation complex and mecciRNAs interact with mitochondrial permeability transition pore and its regulators including TRAP1 (TNF receptor-associated protein 1) and CypD (cyclophilin D). MecciRNAs regulate mitochondrial levels of TRAP1 and CypD to modulate the opening of mitochondrial permeability transition pore and the release of mitochondrial reactive oxygen species. Exogenously applied mecciRNAs interact with cytosolic TRAP1 and increase mitochondrial levels of TRAP1, and lead to a more closed state of mitochondrial permeability transition pore to constrain deleterious reactive oxygen species release. HF conditions lead to stimulated mecciRNA degradation, and administration of in vitro synthesized mecciRNAs exhibits substantial protective effects in both doxorubicin- and pressure overload-induced mouse models of HF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究表明，MeccirNA的快速降解以及线粒体活性氧的相关调节释放线粒体通透性过渡孔通过Meccirnas导致Meccirna Decradation Decradation Decradation degradation和Exenos Megenos Megenos Megenos Megenos Myternos cashement Mevers topernos Meption hf tose Myse hf hf。</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39973625/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39973625</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070840>10.1161/CIRCULATIONAHA.124.070840</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39973625</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Xu Liu</dc:creator><dc:creator> Qinwei Wang</dc:creator><dc:creator> Xinya Li</dc:creator><dc:creator> Yan Yang</dc:creator><dc:creator> Yuqi Deng</dc:creator><dc:creator> Xiaolin Wang</dc:creator><dc:creator> Peipei Wang</dc:creator><dc:creator> Liang Chen</dc:creator><dc:creator> Likun Ma</dc:creator><dc:creator> Ge Shan</dc:creator><dc:date> 2025-02-20</dc:date><dc:source> Circulation</dc:source><dc:title> Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA</dc:title><dc:identifier> pmid:39973625</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.070840</dc:identifier></item><item><title> Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title><link/> https://pubmed.ncbi.nlm.nih.gov/39973614/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description> This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 20. doi: 10.1161/CIR.0000000000001297. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39973614/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39973614</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001297>10.1161/CIR.0000000000001297</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39973614</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Jonathan H Kim</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:creator> Benjamin D Levine</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Sharlene M Day</dc:creator><dc:creator> Elizabeth H Dineen</dc:creator><dc:creator> J Sawalla Guseh</dc:creator><dc:creator> Andre La Gerche</dc:creator><dc:creator> Rachel Lampert</dc:creator><dc:creator> Matthew W Martinez</dc:creator><dc:creator> Michael Papadakis</dc:creator><dc:creator> Dermot M Phelan</dc:creator><dc:creator> Keri M Shafer</dc:creator><dc:creator> American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and American College of Cardiology</dc:creator><dc:date> 2025-02-20</dc:date><dc:source> Circulation</dc:source><dc:title> Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title><dc:identifier> pmid:39973614</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001297</dc:identifier></item><item><title> Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/39973613/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250222071750&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070865. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We conducted a population-based cohort study using linked administrative data sets of people ≥66 years of age who newly initiated warfarin or direct oral anticoagulants after diagnosis with AF between 2008 and 2022. Follow-up was 2 years after starting anticoagulation. We excluded patients with valvular disease, chronic dialysis, venous thromboembolism, previous cancer, or previously documented bleeding. Bleeding was identified from hospital/emergency department discharge records and physician billings, then handled as a time-varying covariate in cause-specific regression models while adjusting for baseline characteristics. The primary outcome was incident malignancy. We also determined the site of origin of the malignancy and the stage at diagnosis if indicated in the Ontario Cancer Registry. Analyses were repeated while limiting the exposure to specific bleeding sites. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 119 480 people (mean age, 77.4 years; 52% male) who started anticoagulants, 26 037 (21.8%) had documented bleeding, and 5800 (4.9%) were diagnosed with malignancy within the next 2 years. Bleeding was associated with a higher hazard of cancer diagnosis with a hazard ratio (HR) of 4.0 (95% CI, 3.8-4.3). The HRs for any malignancy were 5.0 (95% CI, 4.6-5.5) for gastrointestinal, 5.0 (95% CI, 4.4-5.7) for genitourinary, 4.0 (95% CI, 3.5-4.6) for respiratory, 1.8 (95% CI, 1.4-2.2) for intracranial, and 1.5 (95% CI, 1.2-2.0) for nasopharyngeal bleeds. The HRs were substantially higher for cancers concordant with the bleeding site (gastrointestinal, 15.4; genitourinary, 11.8; respiratory, 10.1). Cancers were diagnosed at an earlier stage after bleeding (27.6% stage 4 after bleeding versus 31.3% without bleeding; <i>P</i> =0.029). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39973613/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250222071750&v=2.18.0.post9+e462414">39973613</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070865>10.1161/CIRCULATIONAHA.124.070865</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39973613</guid><pubDate> Thu, 20 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Kavi Grewal</dc:creator><dc:creator> Xuesong Wang</dc:creator><dc:creator> Peter C Austin</dc:creator><dc:creator> Cynthia A Jackevicius</dc:creator><dc:creator> Inbar Nardi-Admon</dc:creator><dc:creator> Dennis T Ko</dc:creator><dc:creator> Douglas S Lee</dc:creator><dc:creator> Paaladinesh Thavendiranathan</dc:creator><dc:creator> Michael Fradley</dc:creator><dc:creator> Paul Dorian</dc:creator><dc:creator> Husam Abdel-Qadir</dc:creator><dc:date> 2025-02-20</dc:date><dc:source> Circulation</dc:source><dc:title> Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study</dc:title><dc:identifier> pmid:39973613</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.070865</dc:identifier></item></channel></rss>